Autolus Therapeutics plc Files Q2 2024 10-Q
Ticker: AUTL · Form: 10-Q · Filed: 2024-08-08T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, financials, biotech
TL;DR
Autolus Therapeutics Q2 10-Q filed. Financials and ops update.
AI Summary
Autolus Therapeutics plc filed its 10-Q for the period ending June 30, 2024. The company reported its financial results for the second quarter and first half of the year. Key financial data and operational updates are detailed within the filing.
Why It Matters
This filing provides investors with a detailed look at Autolus Therapeutics' financial health and operational progress during the second quarter of 2024, crucial for understanding their drug development trajectory.
Risk Assessment
Risk Level: medium — As a biotechnology company, Autolus Therapeutics faces inherent risks related to drug development, clinical trials, regulatory approvals, and market competition.
Key Numbers
- 2024-06-30 — Reporting Period End Date (Indicates the end of the financial quarter being reported.)
- 2024-08-08 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
- 2023-12-31 — Prior Year End Date (Provides a comparison point for financial performance.)
Key Players & Entities
- Autolus Therapeutics plc (company) — Filer of the 10-Q
- 20240630 (date) — End of reporting period
- 20240808 (date) — Filing date
FAQ
What is the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing is the quarter ended June 30, 2024.
When was this 10-Q filed with the SEC?
This 10-Q was filed on August 8, 2024.
What is the company's Central Index Key (CIK)?
The company's Central Index Key (CIK) is 0001730463.
What is the Standard Industrial Classification (SIC) code for Autolus Therapeutics plc?
The SIC code for Autolus Therapeutics plc is 2836, which corresponds to Biological Products (No Diagnostic Substances).
What is the fiscal year end for Autolus Therapeutics plc?
The fiscal year end for Autolus Therapeutics plc is December 31.
From the Filing
0001730463-24-000093.txt : 20240808 0001730463-24-000093.hdr.sgml : 20240808 20240808162126 ACCESSION NUMBER: 0001730463-24-000093 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 80 CONFORMED PERIOD OF REPORT: 20240630 FILED AS OF DATE: 20240808 DATE AS OF CHANGE: 20240808 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Autolus Therapeutics plc CENTRAL INDEX KEY: 0001730463 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38547 FILM NUMBER: 241188741 BUSINESS ADDRESS: STREET 1: THE MEDIAWORKS STREET 2: 191 WOOD LANE CITY: LONDON STATE: X0 ZIP: W12 7FP BUSINESS PHONE: 44 20 3829 6230 MAIL ADDRESS: STREET 1: THE MEDIAWORKS STREET 2: 191 WOOD LANE CITY: LONDON STATE: X0 ZIP: W12 7FP FORMER COMPANY: FORMER CONFORMED NAME: Autolus Therapeutics Ltd DATE OF NAME CHANGE: 20180205 10-Q 1 autl-20240630.htm 10-Q autl-20240630 0001730463 false 2024 Q2 12/31 True 280 xbrli:shares iso4217:USD iso4217:USD xbrli:shares iso4217:GBP xbrli:shares xbrli:pure autl:financialInstrument autl:unit autl:performanceObligation autl:vote autl:payment autl:contract iso4217:EUR autl:director 0001730463 2024-01-01 2024-06-30 0001730463 dei:AdrMember 2024-01-01 2024-06-30 0001730463 autl:OrdinarySharesMember 2024-01-01 2024-06-30 0001730463 2024-08-06 0001730463 2024-06-30 0001730463 2023-12-31 0001730463 autl:OrdinarySharesMember 2024-06-30 0001730463 autl:OrdinarySharesMember 2023-12-31 0001730463 autl:DeferredClassASharesMember 2023-12-31 0001730463 autl:DeferredClassASharesMember 2024-06-30 0001730463 autl:DeferredClassBSharesMember 2024-06-30 0001730463 autl:DeferredClassBSharesMember 2023-12-31 0001730463 autl:DeferredClassCSharesMember 2023-12-31 0001730463 autl:DeferredClassCSharesMember 2024-06-30 0001730463 us-gaap:LicenseMember 2024-04-01 2024-06-30 0001730463 us-gaap:LicenseMember 2023-04-01 2023-06-30 0001730463 us-gaap:LicenseMember 2024-01-01 2024-06-30 0001730463 us-gaap:LicenseMember 2023-01-01 2023-06-30 0001730463 2024-04-01 2024-06-30 0001730463 2023-04-01 2023-06-30 0001730463 2023-01-01 2023-06-30 0001730463 us-gaap:CommonStockMember autl:OrdinarySharesMember 2023-12-31 0001730463 us-gaap:CommonStockMember autl:DeferredClassASharesMember 2023-12-31 0001730463 us-gaap:CommonStockMember autl:DeferredClassBSharesMember 2023-12-31 0001730463 us-gaap:CommonStockMember autl:DeferredClassCSharesMember 2023-12-31 0001730463 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001730463 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001730463 us-gaap:RetainedEarningsMember 2023-12-31 0001730463 us-gaap:CommonStockMember autl:OrdinarySharesMember 2024-01-01 2024-03-31 0001730463 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001730463 2024-01-01 2024-03-31 0001730463 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001730463 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001730463 us-gaap:CommonStockMember autl:OrdinarySharesMember 2024-03-31 0001730463 us-gaap:CommonStockMember autl:DeferredClassASharesMember 2024-03-31 0001730463 us-gaap:CommonStockMember autl:DeferredClassBSharesMember 2024-03-31 0001730463 us-gaap:CommonStockMember autl:DeferredClassCSharesMember 2024-03-31 0001730463 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001730463 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001730463 us-gaap:RetainedEarningsMember 2024-03-31 0001730463 2024-03-31 0001730463 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001730463 us-gaap:CommonStockMember autl:OrdinarySharesMember 2024-04-01 2024-06-30 0001730463 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-06-30 0001730463 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001730463 us-gaap:CommonStockMember autl:OrdinarySharesMember 2024-06-30 0001730463 us-gaap:Comm